News in brief

Lonza completes Capsugel acquisition for $5.5 billion

© iStock/Kritchanut

Switzerland’s Lonza has completed the acquisition of Capsugel S.A. from KKR after receiving all the required regulatory approvals.

The acquisition aligns with Lonza’s strategy to accelerate its growth and ability to deliver value along the healthcare continuum, said the company in a release.

“Lonza and Capsugel have a highly synergistic customer base and market approach, complementary business models and closely aligned corporate cultures with a strong commitment to ethics and compliance. All of these aspects will facilitate a seamless integration,” said Richard Ridinger, Lonza's CEO.

The $5.5 billion transaction price includes approximately $2 billion for refinancing of existing Capsugel debt. Capsugel’s business will continue to operate in its existing structure until the full integration has been completed, said Lonza.

Acquisition trail

Last year, Lonza acquired Benicia, CA-based InterHealth Nutraceuticals, a nutritional ingredient research, development, and manufacture company, for $300 million.

InterHealth’s flagship ingredient is UC-II for join-health, although the company offers more than 15 branded ingredients.

Related News

The private equity firm will be the majority owner of Nature's bounty. ©iStock

KKR signs deal to acquire majority stake in Nature's Bounty

Pharmavite appoints Jeff Boutelle as new CEO

Pharmavite appoints Jeff Boutelle as new CEO

Photo: iStock/Macgyverhh

Innophos increases focus on dietary supplements through $125m acquisition of Novel Ingredients

(Image: iStock)

Lonza acquires InterHealth for $300m

© iStock/Kurhan

L-carnitine combination may promote muscle growth, strength in older adults